{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:41:37Z","timestamp":1771573297422,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Identifying patients with locally advanced head and neck carcinoma on high risk of recurrence after definitive concurrent radiochemotherapy is of key importance for the selection for consolidation therapy and for individualized treatment intensification. In this multicenter study we analyzed recurrence-associated single-nucleotide polymorphisms (SNPs) in DNA repair genes in tumor DNA from 132 patients with locally advanced head and neck carcinoma (LadHnSCC). Patients were treated with definitive radiotherapy and simultaneous cisplatin-based chemotherapy at six partner sites of the German Cancer Consortium (DKTK) Radiation Oncology Group from 2005 to 2011. For validation, a group of 20 patients was available. Score selection method using proportional hazard analysis and leave-one-out cross-validation were performed to identify markers associated with outcome. The SNPs rs1799793 and rs13181 were associated with survival and the same SNPs and in addition rs17655 with freedom from loco-regional relapse (ffLRR) in the trainings datasets from all patients. The homozygote major rs1799793 genotype at the <jats:italic>ERCC2<\/jats:italic> gene was associated with better (Hazard ratio (HR): 0.418 (0.234\u20130.744), <jats:italic>p<\/jats:italic>\u2009=\u20090.003) and the homozygote minor rs13181 genotype at <jats:italic>ERCC2<\/jats:italic> with worse survival (HR: 2.074, 95% CI (1.177\u20133.658), <jats:italic>p<\/jats:italic>\u2009=\u20090.017) in comparison to the other genotypes. At the ffLRR endpoint, rs1799793 and rs13181 had comparable prognostic value. The rs1799793 and rs13181 genotypes passed the leave-one-out cross-validation procedure and associated with survival and ffLRR in patients with LadHnSCC treated with definitive radiochemotherapy. While findings were confirmed in a small validation dataset, further validation is underway within a prospective biomarker study of the DKTK.<\/jats:p>","DOI":"10.1038\/s41397-020-0174-1","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T05:02:16Z","timestamp":1592283736000},"page":"37-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3218-0539","authenticated-orcid":false,"given":"Maja","family":"Guberina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Sak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"P\u00f6ttgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingeborg","family":"Tinhofer-Keilholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Budach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Balermpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Von der Gr\u00fcn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus Michael","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Gkika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8016-5897","authenticated-orcid":false,"given":"Amir","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffi","family":"Pigorsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephani E.","family":"Combs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"M\u00f6nnich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"De-Colle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Welz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-1721","authenticated-orcid":false,"given":"Annett","family":"Linge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Lohaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Baretton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Gauler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9340-974X","authenticated-orcid":false,"given":"Michael","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mechthild","family":"Krause","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Bankfalvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"H\u00f6ing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"174_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24\u201335.","journal-title":"N Engl J Med"},{"key":"174_CR2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S1470-2045(17)30458-8","volume":"18","author":"B Lacas","year":"2017","unstructured":"Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18:1221\u201337.","journal-title":"Lancet Oncol"},{"key":"174_CR3","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.cct.2013.06.011","volume":"36","author":"J Subramanian","year":"2013","unstructured":"Subramanian J, Simon R. Overfitting in prediction models\u2014is it a problem only in high dimensions? Contemp Clin Trials. 2013;36:636\u201341.","journal-title":"Contemp Clin Trials"},{"key":"174_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.prro.2017.02.002","volume":"7","author":"DJ Sher","year":"2017","unstructured":"Sher DJ, Adelstein DJ, Bajaj GK, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2017;7:246\u201353.","journal-title":"Pract Radiat Oncol"},{"key":"174_CR5","first-page":"4899","volume":"62","author":"T Furuta","year":"2002","unstructured":"Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002;62:4899\u2013902.","journal-title":"Cancer Res"},{"key":"174_CR6","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.2174\/0929867324666170124145557","volume":"24","author":"J Blasiak","year":"2017","unstructured":"Blasiak J. DNA-damaging anticancer drugs\u2014a perspective for DNA repair\u2014oriented therapy. Curr Med Chem. 2017;24:1488\u2013503.","journal-title":"Curr Med Chem"},{"key":"174_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.dnarep.2015.05.003","volume":"31","author":"L Farnebo","year":"2015","unstructured":"Farnebo L, Stjernstrom A, Fredrikson M, Ansell A, Garvin S, Thunell LK. DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck. DNA Repair. 2015;31:64\u201372.","journal-title":"DNA Repair"},{"key":"174_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/1078-0432.CCR-11-1759","volume":"18","author":"AK Azad","year":"2012","unstructured":"Azad AK, Bairati I, Samson E, et al. Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival. Clin Cancer Res. 2012;18:196\u2013206.","journal-title":"Clin Cancer Res"},{"key":"174_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(11)70302-3","volume":"13","author":"GC Barnett","year":"2012","unstructured":"Barnett GC, Coles CE, Elliott RM, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol. 2012;13:65\u201377.","journal-title":"Lancet Oncol"},{"key":"174_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1776-x","volume":"15","author":"T Melchardt","year":"2015","unstructured":"Melchardt T, Hufnagl C, Magnes T, et al. CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. BMC Cancer. 2015;15:725.","journal-title":"BMC Cancer"},{"key":"174_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ijc.28051","volume":"133","author":"X Song","year":"2013","unstructured":"Song X, Sturgis EM, Jin L, Wang Z, Wei Q, Li G. Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx. Int J Cancer. 2013;133:695\u2013704.","journal-title":"Int J Cancer"},{"key":"174_CR12","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1158\/1055-9965.EPI-11-0520","volume":"20","author":"S Zhong","year":"2011","unstructured":"Zhong S, Nukui T, Buch S, et al. Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent. Cancer Epidemiol Biomark Prev. 2011;20:2429\u201337.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"174_CR13","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.ijrobp.2008.08.073","volume":"73","author":"J Werbrouck","year":"2009","unstructured":"Werbrouck J, De Ruyck K, Duprez F, et al. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys. 2009;73:1187\u201395.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"174_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.radonc.2016.11.008","volume":"121","author":"A Linge","year":"2016","unstructured":"Linge A, Lohaus F, Lock S, et al. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Oncol. 2016;121:364\u201373.","journal-title":"Radiother Oncol"},{"key":"174_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.radonc.2017.10.008","volume":"126","author":"C De-Colle","year":"2018","unstructured":"De-Colle C, Menegakis A, Monnich D, et al. SDF-1\/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiother Oncol. 2018;126:125\u201331.","journal-title":"Radiother Oncol"},{"key":"174_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/carcin\/21.4.551","volume":"21","author":"RM Lunn","year":"2000","unstructured":"Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis. 2000;21:551\u20135.","journal-title":"Carcinogenesis"},{"key":"174_CR17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ijrobp.2006.06.029","volume":"66","author":"J Carles","year":"2006","unstructured":"Carles J, Monzo M, Amat M, et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;66:1022\u201330.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"174_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10552-014-0346-x","volume":"25","author":"AB Wyss","year":"2014","unstructured":"Wyss AB, Weissler MC, Avery CL, et al. Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival. Cancer Causes Control. 2014;25:437\u201350.","journal-title":"Cancer Causes Control"},{"key":"174_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.dnarep.2016.02.006","volume":"40","author":"KD Mumbrekar","year":"2016","unstructured":"Mumbrekar KD, Goutham HV, Vadhiraja BM, Bola Sadashiva SR. Polymorphisms in double strand break repair related genes influence radiosensitivity phenotype in lymphocytes from healthy individuals. DNA Repair. 2016;40:27\u201334.","journal-title":"DNA Repair"},{"key":"174_CR20","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00280-016-3015-9","volume":"77","author":"F Li","year":"2016","unstructured":"Li F, Xie X, Ren X, Zhang J. A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy. Cancer Chemother Pharmacol. 2016;77:1183\u201391.","journal-title":"Cancer Chemother Pharmacol"},{"key":"174_CR21","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/ije\/dyi169","volume":"34","author":"C Minelli","year":"2005","unstructured":"Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol. 2005;34:1319\u201328.","journal-title":"Int J Epidemiol"},{"key":"174_CR22","unstructured":"SAS Institute Inc. SAS\/STAT 9.2 user\u2019s guide. SAS Institute Inc.: Cary, NC; 2008. https:\/\/support.sas.com\/en\/books\/authors.html."},{"key":"174_CR23","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/gepi.20612","volume":"35","author":"D Shriner","year":"2011","unstructured":"Shriner D. Approximate and exact tests of Hardy-Weinberg equilibrium using uncertain genotypes. Genet Epidemiol. 2011;35:632\u20137.","journal-title":"Genet Epidemiol"},{"key":"174_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.compbiomed.2014.11.015","volume":"57","author":"C Rushing","year":"2015","unstructured":"Rushing C, Bulusu A, Hurwitz HI, Nixon AB, Pang H. A leave-one-out cross-validation SAS macro for the identification of markers associated with survival. Comput Biol Med. 2015;57:123\u20139.","journal-title":"Comput Biol Med"},{"key":"174_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000179560","volume":"67","author":"S Wellek","year":"2009","unstructured":"Wellek S, Ziegler A. A genotype-based approach to assessing the association between single nucleotide polymorphisms. Hum Hered. 2009;67:128\u201339.","journal-title":"Hum Hered"},{"key":"174_CR26","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2307\/2531492","volume":"45","author":"MS Pepe","year":"1989","unstructured":"Pepe MS, Fleming TR. Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. Biometrics. 1989;45:497\u2013507.","journal-title":"Biometrics"},{"key":"174_CR27","doi-asserted-by":"publisher","first-page":"D930","DOI":"10.1093\/nar\/gkr917","volume":"40","author":"LD Ward","year":"2011","unstructured":"Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2011;40:D930\u20134.","journal-title":"Nucleic Acids Res"},{"key":"174_CR28","doi-asserted-by":"publisher","first-page":"16190","DOI":"10.18632\/oncotarget.7668","volume":"8","author":"L Lopes-Aguiar","year":"2017","unstructured":"Lopes-Aguiar L, Costa EF, Nogueira GA, et al. XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation. Oncotarget. 2017;8:16190\u2013201.","journal-title":"Oncotarget"},{"key":"174_CR29","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1002\/lary.23572","volume":"122","author":"XC Wan","year":"2012","unstructured":"Wan XC, Egloff AM, Johnson J. Histological assessment of cervical lymph node identifies patients with head and neck squamous cell carcinoma (HNSCC): who would benefit from chemoradiation after surgery? Laryngoscope. 2012;122:2712\u201322.","journal-title":"Laryngoscope"},{"key":"174_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cbi.2016.12.015","volume":"263","author":"G Zhang","year":"2017","unstructured":"Zhang G, Guan Y, Zhao Y, et al. ERCC2\/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway. Chem Biol Interact. 2017;263:55\u201365.","journal-title":"Chem Biol Interact"},{"key":"174_CR31","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1007\/s13277-013-1519-z","volume":"35","author":"S-X Li","year":"2014","unstructured":"Li S-X, Dai Q-S, Chen S-X, et al. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis. Tumour Biol. 2014;35:3905\u201315.","journal-title":"Tumour Biol"},{"key":"174_CR32","doi-asserted-by":"publisher","first-page":"D877","DOI":"10.1093\/nar\/gkv1340","volume":"44","author":"LD Ward","year":"2016","unstructured":"Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res. 2016;44:D877\u201381.","journal-title":"Nucleic Acids Res"},{"key":"174_CR33","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/carcin\/bgs107","volume":"33","author":"F Moisan","year":"2012","unstructured":"Moisan F, Laroche-Clary A, Auzanneau C, et al. Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity. Carcinogenesis. 2012;33:962\u20138.","journal-title":"Carcinogenesis"},{"key":"174_CR34","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/carcin\/bgg115","volume":"24","author":"WM Gao","year":"2003","unstructured":"Gao WM, Romkes M, Day RD, et al. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. Carcinogenesis. 2003;24:1671\u20136.","journal-title":"Carcinogenesis"},{"key":"174_CR35","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1002\/jcb.26147","volume":"118","author":"SN Yu","year":"2017","unstructured":"Yu SN, Liu GF, Li XF, Fu BH, Dong LX, Zhang SH. Evaluation of prediction of polymorphisms of DNA repair genes on the efficacy of platinum-based chemotherapy in patients with non-small cell lung cancer: a network meta-analysis. J Cell Biochem. 2017;118:4782\u201391.","journal-title":"J Cell Biochem"},{"key":"174_CR36","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s13277-013-1493-5","volume":"35","author":"Y Yang","year":"2014","unstructured":"Yang Y, Xian L. The association between the ERCC1\/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumor Biol. 2014;35:2905\u201321.","journal-title":"Tumor Biol"},{"key":"174_CR37","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.2217\/pgs.13.169","volume":"14","author":"L van Huis-Tanja","year":"2013","unstructured":"van Huis-Tanja L, Kweekel D, Gelderblom H, et al. Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. Pharmacogenomics. 2013;14:2005\u201312.","journal-title":"Pharmacogenomics"},{"key":"174_CR38","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014;4:1140\u201353.","journal-title":"Cancer Discov"}],"updated-by":[{"DOI":"10.1038\/s41397-020-00193-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000}}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-020-0174-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-020-0174-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-020-0174-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:00:34Z","timestamp":1684616434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-020-0174-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1038\/s41397-020-0174-1","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41397-020-00193-6","asserted-by":"object"}]},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"23 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this Article contained an error in the spelling of the author Eleni Gkika, which was incorrectly given as Eleni Gikka. As well as the author Stephanie E. Combs, this was incorrectly given as Stephanie Combs. Both have now been corrected in the PDF and HTML versions of the Article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MG, AS, CP, IT, VB, PB, JVG, CMR, EG, A-LG, AB, BH, SL, AA, JD, CB, SP, SC, AL, FL, GB, TG, MS: all authors declare that they have no conflict of interest. MB: In the past 5 years, MB attended an advisory board meeting of MERCK KGaA (Darmstadt), for which the University of Dresden received a travel grant. He further received funding for his research projects and for educational grants to the University of Dresden by Teutopharma GmbH (2011- 2015), IBA (2016), Bayer AG (2016-2018), Merck KGaA (2014-open), Medipan GmbH (2014-2018). He is on the supervisory board of HI-STEM gGmbH (Heidelberg) for the German Cancer Research Center (DKFZ, Heidelberg) and also member of the supervisory body of the Charit\u00e9 University Hospital, Berlin. As former chair of OncoRay (Dresden) and present CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg), he has been or is still responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he discussed potential projects with and has signed\/signs contracts for his institute(s) and for the staff for research funding and\/or collaborations with industry and academia, worldwide, including but not limited to pharmaceutical corporations like Bayer, Boehringer Ingelheim, Bosch, Roche and other corporations like Siemens, IBA, Varian, Elekta, Bruker and others. In this role, he was\/is further responsible for commercial technology transfer activities of his institute(s), including the DKFZ-PSMA617 related patent portfolio [WO2015055318 (A1), ANTIGEN (PSMA)] and similar IP portfolios. He confirms that to the best of his knowledge none of the above funding sources was involved in the preparation of this paper. MS: Research grant was contributed by AstraZeneca in 2019 and 2020. MS confirms that the above mentioned funding source was not involved in the study design or materials used, neither in the collection, analysis, and interpretation of data nor in the writing of the paper. Consultant (compensated): AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Roche. Honoraries for CME presentations: Abbvie, Alexion, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Lilly, MSD, Novartis, Pierre Fabre. Research funding to institution: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis. MK: conflict of interest statement. In the past 5 years, MK received funding for her research projects by IBA (2016), Merck KGaA (2014\u20132018 for preclinical study; 2018\u20132020 for clinical study), Medipan GmbH (2014\u20132018), Attomol GmbH (2019\u20132021), GA Generic Assays GmbH (2019\u20132021), BTU Cottbus-Senftenberg (2019\u20132021), Gesellschaft f\u00fcr medizinische und wissenschaftliche genetische Analysen (2019\u20132021), Lipotype GmbH (2019\u20132021), PolyAn GmbH (2019\u20132021). For the present study, MK confirms that none of the above mentioned funding sources were involved in the study design or materials used, nor in the collection, analysis and interpretation of data nor in the writing of the paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Statement on ethics approval and consent by the ethics committee of the Faculty of Medicine, University Duisburg-Essen, University Hospital Essen (Prof. Havers, Prof. Schara) is available: registration number 14-5816-BO.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}